Published in FEBS J on August 31, 2010
Proteoglycans in cancer biology, tumour microenvironment and angiogenesis. J Cell Mol Med (2011) 2.21
Proteoglycans in health and disease: novel regulatory signaling mechanisms evoked by the small leucine-rich proteoglycans. FEBS J (2010) 1.82
Heparanase Enhances Tumor Growth and Chemoresistance by Promoting Autophagy. Cancer Res (2015) 1.59
Heparanase regulates secretion, composition, and function of tumor cell-derived exosomes. J Biol Chem (2013) 1.49
Significance of heparanase in cancer and inflammation. Cancer Microenviron (2011) 1.46
Agrin and perlecan mediate tumorigenic processes in oral squamous cell carcinoma. PLoS One (2014) 1.42
SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis. Clin Cancer Res (2011) 1.40
PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models. Br J Cancer (2011) 1.27
The heparanase/syndecan-1 axis in cancer: mechanisms and therapies. FEBS J (2013) 1.24
Heparanase plays a dual role in driving hepatocyte growth factor (HGF) signaling by enhancing HGF expression and activity. J Biol Chem (2010) 1.16
Heparanase-mediated loss of nuclear syndecan-1 enhances histone acetyltransferase (HAT) activity to promote expression of genes that drive an aggressive tumor phenotype. J Biol Chem (2011) 1.15
Prostaglandins in cancer cell adhesion, migration, and invasion. Int J Cell Biol (2012) 1.09
Cancer becomes wasteful: emerging roles of exosomes(†) in cell-fate determination. J Extracell Vesicles (2013) 1.04
Heparanase cooperates with Ras to drive breast and skin tumorigenesis. Cancer Res (2014) 0.99
An artificial miRNA against HPSE suppresses melanoma invasion properties, correlating with a down-regulation of chemokines and MAPK phosphorylation. PLoS One (2012) 0.99
Sulfated hexasaccharides attenuate metastasis by inhibition of P-selectin and heparanase. Neoplasia (2011) 0.99
Heparanase induces signal transducer and activator of transcription (STAT) protein phosphorylation: preclinical and clinical significance in head and neck cancer. J Biol Chem (2011) 0.98
Heparanase enhances the insulin receptor signaling pathway to activate extracellular signal-regulated kinase in multiple myeloma. J Biol Chem (2012) 0.94
Deciphering mode of action of heparanase using structurally defined oligosaccharides. J Biol Chem (2012) 0.94
Involvement of heparanase in atherosclerosis and other vessel wall pathologies. Matrix Biol (2013) 0.93
Insights into the key roles of proteoglycans in breast cancer biology and translational medicine. Biochim Biophys Acta (2015) 0.92
Impact of heparanase and the tumor microenvironment on cancer metastasis and angiogenesis: basic aspects and clinical applications. Rambam Maimonides Med J (2011) 0.92
PG545, a heparan sulfate mimetic, reduces heparanase expression in vivo, blocks spontaneous metastases and enhances overall survival in the 4T1 breast carcinoma model. PLoS One (2012) 0.91
Heparanase enhances myeloma progression via CXCL10 downregulation. Leukemia (2014) 0.90
LRP-1: a checkpoint for the extracellular matrix proteolysis. Biomed Res Int (2013) 0.90
Lentiviral miR30-based RNA interference against heparanase suppresses melanoma metastasis with lower liver and lung toxicity. Int J Biol Sci (2013) 0.88
Elevated urine heparanase levels are associated with proteinuria and decreased renal allograft function. PLoS One (2012) 0.86
Proteoglycans regulate autophagy via outside-in signaling: an emerging new concept. Matrix Biol (2015) 0.84
The heparan sulfate mimetic PG545 interferes with Wnt/β-catenin signaling and significantly suppresses pancreatic tumorigenesis alone and in combination with gemcitabine. Oncotarget (2015) 0.84
Heparanase inhibits osteoblastogenesis and shifts bone marrow progenitor cell fate in myeloma bone disease. Bone (2013) 0.83
Evidence for a genetic basis of urogenital carcinoma in the wild California sea lion. Proc Biol Sci (2014) 0.82
MYCN-dependent expression of sulfatase-2 regulates neuroblastoma cell survival. Cancer Res (2014) 0.82
Fibroblast EXT1-levels influence tumor cell proliferation and migration in composite spheroids. PLoS One (2012) 0.82
Heparan Sulfate Proteoglycans Regulate Fgf Signaling and Cell Polarity during Collective Cell Migration. Cell Rep (2015) 0.82
Heparanase-induced shedding of syndecan-1/CD138 in myeloma and endothelial cells activates VEGFR2 and an invasive phenotype: prevention by novel synstatins. Oncogenesis (2016) 0.81
Overexpression of heparanase multiple antigenic peptide 2 is associated with poor prognosis in gastric cancer: Potential for therapy. Oncol Lett (2012) 0.81
Heparanase regulation of cancer, autophagy and inflammation: new mechanisms and targets for therapy. FEBS J (2016) 0.80
Anti-metastatic semi-synthetic sulfated maltotriose C-C linked dimers. Synthesis and characterisation. Molecules (2012) 0.80
Nuclear heparanase-1 activity suppresses melanoma progression via its DNA-binding affinity. Oncogene (2015) 0.79
Expression of heparanase in soft tissue sarcomas of adults. J Exp Clin Cancer Res (2014) 0.79
Clinical significance of heparanase splice variant (t5) in renal cell carcinoma: evaluation by a novel t5-specific monoclonal antibody. PLoS One (2012) 0.79
Heparanase is required for activation and function of macrophages. Proc Natl Acad Sci U S A (2016) 0.79
Chemotherapy induces expression and release of heparanase leading to changes associated with an aggressive tumor phenotype. Matrix Biol (2016) 0.79
Over-sulfated glycosaminoglycans are alternative selectin ligands: insights into molecular interactions and possible role in breast cancer metastasis. Clin Exp Metastasis (2013) 0.78
Over-expression of human endosulfatase-1 exacerbates cadmium-induced injury to transformed human lung cells in vitro. Toxicol Appl Pharmacol (2012) 0.78
Bioengineered heparins and heparan sulfates. Adv Drug Deliv Rev (2015) 0.78
Heparan sulfate differences in rheumatoid arthritis versus healthy sera. Matrix Biol (2014) 0.78
Suramin inhibits cell proliferation in ovarian and cervical cancer by downregulating heparanase expression. Cancer Cell Int (2015) 0.78
Tissue-specificity of heparan sulfate biosynthetic machinery in cancer. Cell Adh Migr (2015) 0.78
Heparanase promotes myeloma progression by inducing mesenchymal features and motility of myeloma cells. Oncotarget (2016) 0.77
Heparan sulfate mimetic PG545-mediated antilymphoma effects require TLR9-dependent NK cell activation. J Clin Invest (2015) 0.77
Heparanase 2 expression inversely correlates with bladder carcinoma grade and stage. Oncotarget (2016) 0.77
Heparanase interacts with resistin and augments its activity. PLoS One (2014) 0.77
Extracellular matrix and the myeloid-in-myeloma compartment: balancing tolerogenic and immunogenic inflammation in the myeloma niche. J Leukoc Biol (2017) 0.77
Fibroblast growth factors as tissue repair and regeneration therapeutics. PeerJ (2016) 0.77
DNA methylation of heparanase promoter influences its expression and associated with the progression of human breast cancer. PLoS One (2014) 0.76
Synthesis of a pseudo-disaccharide library and its application to the characterisation of the heparanase catalytic site. PLoS One (2013) 0.76
The prognostic significance of heparanase expression in metastatic melanoma. Oncotarget (2016) 0.75
Involvement of Heparanase in Empyema: Implication for Novel Therapeutic Approaches. J Clin Cell Immunol (2015) 0.75
Aberrant gene expression of heparanase in ventricular hypertrophy induced by monocrotaline in rats. J Vet Med Sci (2015) 0.75
The Heparanase Inhibitor PG545 Attenuates Colon Cancer Initiation and Growth, Associating with Increased p21 Expression. Neoplasia (2017) 0.75
Conformational changes of 1-4-glucopyranosyl residues of a sulfated C-C linked hexasaccharide. Carbohydr Res (2014) 0.75
In vitro and ex vivo evaluation of a multi-epitope heparinase vaccine for various malignancies. Cancer Sci (2013) 0.75
Heparanase and cancer progression: New directions, new promises. Hum Vaccin Immunother (2016) 0.75
Elevated heparanase expression is associated with poor prognosis in breast cancer: a study based on systematic review and TCGA data. Oncotarget (2017) 0.75
Heparanase overexpression down-regulates syndecan-1 expression in a gallbladder carcinoma cell line. J Int Med Res (2017) 0.75
Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem (1999) 11.87
RNA and disease. Cell (2009) 7.98
Heparin-protein interactions. Angew Chem Int Ed Engl (2002) 7.27
Tumor self-seeding by circulating cancer cells. Cell (2009) 6.66
Proteoglycans: structures and interactions. Annu Rev Biochem (1991) 6.53
Head and neck cancer. N Engl J Med (1993) 6.33
The sweet and sour of cancer: glycans as novel therapeutic targets. Nat Rev Cancer (2005) 5.98
Matrix proteoglycans: from molecular design to cellular function. Annu Rev Biochem (1998) 4.86
Endothelial cell-derived basic fibroblast growth factor: synthesis and deposition into subendothelial extracellular matrix. Proc Natl Acad Sci U S A (1987) 4.83
Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis. Nat Med (1999) 4.22
A heparin-binding angiogenic protein--basic fibroblast growth factor--is stored within basement membrane. Am J Pathol (1988) 3.72
Alternative splicing and disease. Biochim Biophys Acta (2008) 3.47
Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Int J Biochem Cell Biol (2006) 3.24
The putative tumour suppressor EXT1 alters the expression of cell-surface heparan sulfate. Nat Genet (1998) 3.14
Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell (2002) 3.11
Cloning of mammalian heparanase, an important enzyme in tumor invasion and metastasis. Nat Med (1999) 3.06
Heparanase gene silencing, tumor invasiveness, angiogenesis, and metastasis. J Natl Cancer Inst (2004) 2.52
The putative tumor suppressors EXT1 and EXT2 are glycosyltransferases required for the biosynthesis of heparan sulfate. J Biol Chem (1998) 2.47
Syndecans: new kids on the signaling block. Circ Res (2005) 2.43
Loss of HSulf-1 up-regulates heparin-binding growth factor signaling in cancer. J Biol Chem (2003) 2.40
Heparanase enhances syndecan-1 shedding: a novel mechanism for stimulation of tumor growth and metastasis. J Biol Chem (2007) 2.25
Heparan sulfate proteoglycans: heavy hitters in the angiogenesis arena. J Clin Invest (2001) 2.18
Heparanase: structure, biological functions, and inhibition by heparin-derived mimetics of heparan sulfate. Curr Pharm Des (2007) 2.14
Heparanase: busy at the cell surface. Trends Biochem Sci (2009) 2.07
Heparanase as mediator of angiogenesis: mode of action. FASEB J (2001) 2.04
Lymphoma cell-mediated degradation of sulfated proteoglycans in the subendothelial extracellular matrix: relationship to tumor cell metastasis. Cancer Res (1983) 2.04
Mammalian heparanase: what is the message? J Cell Mol Med (2007) 1.91
Syndecans in tumor cell adhesion and signaling. Reprod Biol Endocrinol (2004) 1.88
Proteoglycans in health and disease: novel roles for proteoglycans in malignancy and their pharmacological targeting. FEBS J (2010) 1.83
HSulf-1 modulates HGF-mediated tumor cell invasion and signaling in head and neck squamous carcinoma. Oncogene (2004) 1.82
Proteoglycans in health and disease: novel regulatory signaling mechanisms evoked by the small leucine-rich proteoglycans. FEBS J (2010) 1.82
High heparanase activity in multiple myeloma is associated with elevated microvessel density. Cancer Res (2003) 1.81
Heparanase induces endothelial cell migration via protein kinase B/Akt activation. J Biol Chem (2004) 1.78
Heparan sulfate proteoglycans and heparanase--partners in osteolytic tumor growth and metastasis. Matrix Biol (2004) 1.75
Heparanase stimulation of protease expression implicates it as a master regulator of the aggressive tumor phenotype in myeloma. J Biol Chem (2008) 1.74
Antigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma. J Clin Invest (2009) 1.73
Human heparanase. Purification, characterization, cloning, and expression. J Biol Chem (1999) 1.69
Soluble syndecan-1 promotes growth of myeloma tumors in vivo. Blood (2002) 1.69
Interactions between heparan sulfate and proteins-design and functional implications. Int Rev Cell Mol Biol (2009) 1.67
HSulf-1 and HSulf-2 are potent inhibitors of myeloma tumor growth in vivo. J Biol Chem (2005) 1.66
Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma. Blood (2007) 1.65
Transgenic expression of mammalian heparanase uncovers physiological functions of heparan sulfate in tissue morphogenesis, vascularization, and feeding behavior. FASEB J (2004) 1.64
Heparan sulfate degradation: relation to tumor invasive and metastatic properties of mouse B16 melanoma sublines. Science (1983) 1.63
Heparanase-enhanced shedding of syndecan-1 by myeloma cells promotes endothelial invasion and angiogenesis. Blood (2010) 1.61
Proteoglycans in health and disease: the multiple roles of syndecan shedding. FEBS J (2010) 1.58
Heparan sulfate: a complex polymer charged with biological activity. Chem Rev (2005) 1.57
Cloning and functional expression of a human heparanase gene. Biochem Biophys Res Commun (1999) 1.56
Association of heparanase gene (HPSE) single nucleotide polymorphisms with hematological malignancies. Leukemia (2007) 1.54
Heparanase affects adhesive and tumorigenic potential of human glioma cells. Cancer Res (2003) 1.54
Serum syndecan-1: a new independent prognostic marker in multiple myeloma. Blood (2000) 1.54
Expression of heparanase in normal, dysplastic, and neoplastic human colonic mucosa and stroma. Evidence for its role in colonic tumorigenesis. Am J Pathol (2000) 1.52
Modulation of the heparanase-inhibiting activity of heparin through selective desulfation, graded N-acetylation, and glycol splitting. J Biol Chem (2005) 1.52
The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy. Blood (2007) 1.49
Newly generated heparanase knock-out mice unravel co-regulation of heparanase and matrix metalloproteinases. PLoS One (2009) 1.46
The clinicopathological significance of heparanase and basic fibroblast growth factor expressions in hepatocellular carcinoma. Clin Cancer Res (2001) 1.44
A functional heparan sulfate mimetic implicates both heparanase and heparan sulfate in tumor angiogenesis and invasion in a mouse model of multistage cancer. Oncogene (2005) 1.43
Heparanase promotes growth, angiogenesis and survival of primary breast tumors. Int J Cancer (2006) 1.42
Non-anticoagulant heparins and inhibition of cancer. Pathophysiol Haemost Thromb (2009) 1.41
Heparanase promotes the spontaneous metastasis of myeloma cells to bone. Blood (2004) 1.38
Identification of active-site residues of the pro-metastatic endoglycosidase heparanase. Biochemistry (2000) 1.37
Proteoglycans and tumor progression: Janus-faced molecules with contradictory functions in cancer. Semin Cancer Biol (2002) 1.35
Heparanase augments epidermal growth factor receptor phosphorylation: correlation with head and neck tumor progression. Cancer Res (2008) 1.35
Structure-function approach identifies a COOH-terminal domain that mediates heparanase signaling. Cancer Res (2009) 1.34
Heparan sulfate proteoglycans in invasion and metastasis. Semin Cell Dev Biol (2001) 1.34
Heparanase accelerates wound angiogenesis and wound healing in mouse and rat models. FASEB J (2005) 1.32
Cleavage of macromolecular heparin by an enzyme from mouse mastocytoma. J Biol Chem (1975) 1.32
Heparanase induces VEGF C and facilitates tumor lymphangiogenesis. Int J Cancer (2008) 1.31
Heparanase: one molecule with multiple functions in cancer progression. Connect Tissue Res (2008) 1.29
Heparanase localization and expression by head and neck cancer: correlation with tumor progression and patient survival. Neoplasia (2006) 1.28
Metastatic patterns in squamous cell cancer of the head and neck. Am J Surg (1987) 1.27
Syndecan-1: a dynamic regulator of the myeloma microenvironment. Clin Exp Metastasis (2007) 1.27
Identification and characterization of heparin/heparan sulfate binding domains of the endoglycosidase heparanase. J Biol Chem (2005) 1.27
Function of heparanase in prostate tumorigenesis: potential for therapy. Clin Cancer Res (2008) 1.25
Increased heparanase expression is caused by promoter hypomethylation and up-regulation of transcriptional factor early growth response-1 in human prostate cancer. Clin Cancer Res (2005) 1.25
The development of inhibitors of heparanase, a key enzyme involved in tumour metastasis, angiogenesis and inflammation. Mini Rev Med Chem (2004) 1.24
Mechanism of activation of human heparanase investigated by protein engineering. Biochemistry (2004) 1.21
A phase I biological and pharmacologic study of the heparanase inhibitor PI-88 in patients with advanced solid tumors. Clin Cancer Res (2006) 1.19
Targeting epidermal growth factor receptor in head and neck cancer. Head Neck (2003) 1.16
Site-directed mutagenesis, proteolytic cleavage, and activation of human proheparanase. J Biol Chem (2005) 1.13
A novel human heparanase splice variant, T5, endowed with protumorigenic characteristics. FASEB J (2009) 1.13
Role of promoter methylation in regulation of the mammalian heparanase gene. Oncogene (2003) 1.12
Heparanase-1 expression is associated with the metastatic potential of breast cancer. Surgery (2002) 1.10
A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma. Invest New Drugs (2007) 1.09
Novel aspects of glypican glycobiology. Cell Mol Life Sci (2004) 1.09
Enzymatic depolymerization of heparin-related polysaccharides. Substrate specificities of mouse mastocytoma and human platelet endo-beta-D-glucuronidases. J Biol Chem (1982) 1.08
Heparanase: a key enzyme in invasion and metastasis of gastric carcinoma. Mod Pathol (2002) 1.08
Tumor suppressor p53 regulates heparanase gene expression. Oncogene (2006) 1.07
Frequency and sites of distant metastases in head and neck squamous cell carcinoma. An analysis of 101 cases at autopsy. Arch Otolaryngol Head Neck Surg (1987) 1.06
Promoter CpG hypomethylation and transcription factor EGR1 hyperactivate heparanase expression in bladder cancer. Oncogene (2005) 1.04
Heparanase induces Akt phosphorylation via a lipid raft receptor. Biochem Biophys Res Commun (2007) 1.04
Spatial and temporal heparanase expression in colon mucosa throughout the adenoma-carcinoma sequence. Mod Pathol (2006) 1.02
Unraveling the specificity of heparanase utilizing synthetic substrates. J Biol Chem (2010) 1.02
Undersulfated and glycol-split heparins endowed with antiangiogenic activity. J Med Chem (2004) 0.99
Heparanase expression in malignant salivary gland tumors inversely correlates with long-term survival. Neoplasia (2006) 0.98
Heparanase regulates murine hair growth. Am J Pathol (2005) 0.97
c-Src tyrosine phosphorylation of epidermal growth factor receptor, P190 RhoGAP, and focal adhesion kinase regulates diverse cellular processes. Chem Rev (2001) 0.95
Tumor self-seeding: bidirectional flow of tumor cells. Cell (2009) 0.94
Agrin: an extracellular matrix heparan sulfate proteoglycan involved in cell interactions and synaptogenesis. Perspect Dev Neurobiol (1996) 0.92
Heparanase expression in nasopharyngeal carcinoma inversely correlates with patient survival. Histopathology (2006) 0.92
Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Int J Biochem Cell Biol (2006) 3.24
Heparanase gene silencing, tumor invasiveness, angiogenesis, and metastasis. J Natl Cancer Inst (2004) 2.52
Heparanase enhances syndecan-1 shedding: a novel mechanism for stimulation of tumor growth and metastasis. J Biol Chem (2007) 2.25
Proteoglycans in cancer biology, tumour microenvironment and angiogenesis. J Cell Mol Med (2011) 2.21
Heparanase: structure, biological functions, and inhibition by heparin-derived mimetics of heparan sulfate. Curr Pharm Des (2007) 2.14
Heparanase: busy at the cell surface. Trends Biochem Sci (2009) 2.07
Heparanase induces vascular endothelial growth factor expression: correlation with p38 phosphorylation levels and Src activation. Cancer Res (2006) 2.02
Processing and activation of latent heparanase occurs in lysosomes. J Cell Sci (2004) 1.82
High heparanase activity in multiple myeloma is associated with elevated microvessel density. Cancer Res (2003) 1.81
Heparanase induces endothelial cell migration via protein kinase B/Akt activation. J Biol Chem (2004) 1.78
Heparanase stimulation of protease expression implicates it as a master regulator of the aggressive tumor phenotype in myeloma. J Biol Chem (2008) 1.74
Antigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma. J Clin Invest (2009) 1.73
Soluble syndecan-1 promotes growth of myeloma tumors in vivo. Blood (2002) 1.69
HSulf-1 and HSulf-2 are potent inhibitors of myeloma tumor growth in vivo. J Biol Chem (2005) 1.66
Heparanase alters arterial structure, mechanics, and repair following endovascular stenting in mice. Circ Res (2008) 1.64
Transgenic expression of mammalian heparanase uncovers physiological functions of heparan sulfate in tissue morphogenesis, vascularization, and feeding behavior. FASEB J (2004) 1.64
Heparanase-enhanced shedding of syndecan-1 by myeloma cells promotes endothelial invasion and angiogenesis. Blood (2010) 1.61
Heparanase affects adhesive and tumorigenic potential of human glioma cells. Cancer Res (2003) 1.54
A chemotactic gradient sequestered on endothelial heparan sulfate induces directional intraluminal crawling of neutrophils. Blood (2010) 1.53
Modulation of the heparanase-inhibiting activity of heparin through selective desulfation, graded N-acetylation, and glycol splitting. J Biol Chem (2005) 1.52
The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy. Blood (2007) 1.49
Heparanase regulates secretion, composition, and function of tumor cell-derived exosomes. J Biol Chem (2013) 1.49
Newly generated heparanase knock-out mice unravel co-regulation of heparanase and matrix metalloproteinases. PLoS One (2009) 1.46
Significance of heparanase in cancer and inflammation. Cancer Microenviron (2011) 1.46
Cell surface expression and secretion of heparanase markedly promote tumor angiogenesis and metastasis. Proc Natl Acad Sci U S A (2002) 1.45
Membrane-associated heparan sulfate proteoglycans are involved in the recognition of cellular targets by NKp30 and NKp46. J Immunol (2004) 1.43
Heparanase uptake is mediated by cell membrane heparan sulfate proteoglycans. J Biol Chem (2004) 1.43
Cathepsin L is responsible for processing and activation of proheparanase through multiple cleavages of a linker segment. J Biol Chem (2008) 1.43
Heparanase promotes growth, angiogenesis and survival of primary breast tumors. Int J Cancer (2006) 1.42
Heparanase overexpression reduces carrageenan-induced mechanical and cold hypersensitivity in mice. Neurosci Lett (2011) 1.41
Non-anticoagulant heparins and inhibition of cancer. Pathophysiol Haemost Thromb (2009) 1.41
Heparanase mediates cell adhesion independent of its enzymatic activity. FASEB J (2003) 1.41
Heparanase cleavage of perlecan heparan sulfate modulates FGF10 activity during ex vivo submandibular gland branching morphogenesis. Development (2007) 1.40
SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis. Clin Cancer Res (2011) 1.40
Heparanase promotes the spontaneous metastasis of myeloma cells to bone. Blood (2004) 1.38
The epidermal growth factor-like domains of the human EMR2 receptor mediate cell attachment through chondroitin sulfate glycosaminoglycans. Blood (2003) 1.37
In vivo fragmentation of heparan sulfate by heparanase overexpression renders mice resistant to amyloid protein A amyloidosis. Proc Natl Acad Sci U S A (2005) 1.37
Heparanase augments epidermal growth factor receptor phosphorylation: correlation with head and neck tumor progression. Cancer Res (2008) 1.35
Role of endothelial heparanase in delayed-type hypersensitivity. Blood (2005) 1.35
Structure-function approach identifies a COOH-terminal domain that mediates heparanase signaling. Cancer Res (2009) 1.34
Cellular heparan sulfate participates in the metabolism of prions. J Biol Chem (2003) 1.34
Heparanase accelerates wound angiogenesis and wound healing in mouse and rat models. FASEB J (2005) 1.32
Heparan sulfate is a cellular receptor for purified infectious prions. J Biol Chem (2005) 1.32
Heparanase powers a chronic inflammatory circuit that promotes colitis-associated tumorigenesis in mice. J Clin Invest (2011) 1.32
Heparanase induces VEGF C and facilitates tumor lymphangiogenesis. Int J Cancer (2008) 1.31
Heparanase: one molecule with multiple functions in cancer progression. Connect Tissue Res (2008) 1.29
Heparanase is essential for the development of diabetic nephropathy in mice. Diabetes (2011) 1.29
The impact of heparanese and heparin on cancer metastasis and angiogenesis. Pathophysiol Haemost Thromb (2006) 1.29
Heparanase localization and expression by head and neck cancer: correlation with tumor progression and patient survival. Neoplasia (2006) 1.28
The heparanase system and tumor metastasis: is heparanase the seed and soil? Cancer Metastasis Rev (2011) 1.28
Identification and characterization of heparin/heparan sulfate binding domains of the endoglycosidase heparanase. J Biol Chem (2005) 1.27
Heparin, heparan sulfate and heparanase in inflammatory reactions. Thromb Haemost (2009) 1.27
Function of heparanase in prostate tumorigenesis: potential for therapy. Clin Cancer Res (2008) 1.25
Transgenic or tumor-induced expression of heparanase upregulates sulfation of heparan sulfate. Nat Chem Biol (2007) 1.25
The heparanase/syndecan-1 axis in cancer: mechanisms and therapies. FEBS J (2013) 1.24
Heparanase degrades syndecan-1 and perlecan heparan sulfate: functional implications for tumor cell invasion. J Biol Chem (2003) 1.23
Heparanase regulates levels of syndecan-1 in the nucleus. PLoS One (2009) 1.21
Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells. Blood (2002) 1.19
Heparanase 2 interacts with heparan sulfate with high affinity and inhibits heparanase activity. J Biol Chem (2010) 1.19
Heparanase enhances local and systemic osteolysis in multiple myeloma by upregulating the expression and secretion of RANKL. Cancer Res (2010) 1.18
Syndecan-1 is required for robust growth, vascularization, and metastasis of myeloma tumors in vivo. J Biol Chem (2009) 1.18
Heterodimer formation is essential for heparanase enzymatic activity. Biochem Biophys Res Commun (2003) 1.17
Heparanase plays a dual role in driving hepatocyte growth factor (HGF) signaling by enhancing HGF expression and activity. J Biol Chem (2010) 1.16
Enzymatically quiescent heparanase augments T cell interactions with VCAM-1 and extracellular matrix components under versatile dynamic contexts. J Immunol (2004) 1.16
Expression of heparanase by primary breast tumors promotes bone resorption in the absence of detectable bone metastases. Cancer Res (2005) 1.16
Heparanase-mediated loss of nuclear syndecan-1 enhances histone acetyltransferase (HAT) activity to promote expression of genes that drive an aggressive tumor phenotype. J Biol Chem (2011) 1.15
P-selectin- and heparanase-dependent antimetastatic activity of non-anticoagulant heparins. FASEB J (2007) 1.14
Heparanase facilitates cell adhesion and spreading by clustering of cell surface heparan sulfate proteoglycans. PLoS One (2008) 1.14
Site-directed mutagenesis, proteolytic cleavage, and activation of human proheparanase. J Biol Chem (2005) 1.13
A novel human heparanase splice variant, T5, endowed with protumorigenic characteristics. FASEB J (2009) 1.13
Activation, processing and trafficking of extracellular heparanase by primary human fibroblasts. J Cell Sci (2002) 1.12